In this podcast, Novo Nordisk researcher Dr. Kajsa Kvist and NC TraCS Co-director Dr. John Buse discuss how and why Novo Nordisk became an early participant of the National COVID-19 Collaborative (N3C) as a tool to study the pandemic.

NC State has opened its Biomedical Clinical Manufacturing Facility, and offers UNC researchers and faculty access to its new space and resources. Focusing on stem cells and regenerative medicine, the facility supports Phase I human clinical trials and is helpful to faculty and early startups.

Clinical trials involving patients with type 2 diabetes at high cardiovascular risk have led to advances in our understanding of the effectiveness of two types of drugs – GLP-1 receptor agonists and SGLT2 inhibitors, but only a small proportion of patients are treated with these medications.